SB02024 / Sprint Bioscience, Ono Pharma - LARVOL DELTA

Unleashing anti-tumor immunity: Targeting the autophagy-related protein VPS34 to enhance STING agonist-based therapy. (PubMed, Autophagy Rep) - "In vivo, treatment with the VPS34 inhibitor SB02024 enhances the positive effects of the STING agonist ADU-S100 in melanoma tumor-bearing mice. Thus, our study suggests that VPS34 inhibitors could be used to enhance STING-based anticancer therapies. CCL5 (C-C motif chemokine 5); CXCL10 (C-X-C motif chemokine 10); IFN (interferon); VPS34 (vacuolar protein sorting 34); cGAS (cyclic GMP-AMP Synthase); STING (stimulator of interferon genes protein); cGAMP (2'3'-cyclic guanosine monophosphate-adenosine monophosphate)."

IO biomarker • Journal • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CCL5 • CGAS • CXCL10 • IFNB1 • STING

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy. (PubMed, Mol Oncol) - "These results show that VPS34 inhibition augments the cGAS/STING pathway, leading to greater tumor control through immune-mediated mechanisms. We propose that pharmacological VPS34 inhibition may synergize with emerging therapies targeting the cGAS/STING pathway."

IO biomarker • Journal • Oncology • CGAS • CXCL10 • STING

VPS34 inhibition delays activation-induced STING degradation to prolong STING signaling and improve anti-tumor efficacy in preclinical models. (AACR-NCI-EORTC 2023) - No abstract available

Preclinical • Oncology